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Purpose or Objective  
Nomograms are well established in Low Dose Rate (LDR) 
Brachytherapy to estimate the number of seeds for a 
prostate volume. This concept can be applied to High 
Dose Rate (HDR) Brachytherapy to provide a second check 
of the dose calculation and assess plan and implant 
quality. In 2011, Pujades et al. published findings on the 
use of a nomogram in LDR and HDR prostate 
brachytherapy at 2 separate institutions in Valencia, 
Spain. This work seeks to provide updated patient data to 
validate the use of nomograms in HDR brachytherapy and 
provide a linear fit correlation from the perspective of 
another institution. 
Material and Methods  
The HDR prostate brachytherapy treatment plan data 
were collected from February 2014 through September 
2017, including several monotherapy and boost 
prescriptions from a single institution, Cancer Treatment 
Centers of America Southeastern (CTCA SERMC). The Ir-
192 HDR source and the Varian VariSource™ iX Afterloader 
were used in conjunction with the Varian BrachyVision 
(versions 10.0, 11.0, and 13.6) for treatment planning 
and dose calculation. All treatment plans were evaluated 
based on American Brachytherapy Society consensus 
guidelines for HDR prostate brachytherapy. The air kerma 
strength, Sk, (µGy-m2/h) and total treatment time, T, 
(sec) were recorded and normalized by the prescription 
dose, Rx, (Gy). The normalized total air kerma strength 
was then plotted against the CTV treatment volume, V, 
(cm3). 
Results  
The resulting linear regression line of the data from our 
institution was compared against the data from the two 
different institutions, Institution A and Institution B, 




The standard deviation of the best fit line for CTCA 
SERMC was found to be 0.329 cm2. Out of 375 HDR 
prostate plans, all plans were within 3 standard 
deviations and 98.7% of the plans were within 1 standard 
deviation of the line of best fit. 
The line of best fit for our institution crossed the line of 
best fit for Institution B at 41.15 cm3, demonstrating the 
plans calculated and evaluated at our institution were 
hotter for treatment volumes up to 41.15 cm3 and cooler 
beyond that point. This aligned with the conclusion by 
Pujades et al. that Institution B accepted higher overdose 
volumes in general. 
Conclusion  
Based on these data, this nomogram is being used 
clinically at CTCA SERMC as a safety check of the dose 
calculation. The data points from all recent HDR prostate 
brachytherapy plans are evaluated against this 
nomogram. Those that fall outside 3 standard deviations 
of the best fit line are investigated before treatment 
delivery. Future work will consider additional factors 
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Purpose or Objective  
In August 2017 the Cyberknife 11 (CK-11) version 
including the treatment planning system (TPS) PrecisionTM 
v.1.1 was installed at our institution. The upgrade 
process itself as well as the performance of the new 
hard- and software was evaluated in our clinical 
environment within the framework of a Ramp and 
Monitor program. In this work we report our experiences 
made while performing the upgrade, the time and 
resources needed as well as the impact of this upgrade to 
clinical routine. In addition we evaluated the 
performance of PrecisionTM and compared it with 
MultiPlanTM. 
Material and Methods  
In order to evaluate the performance of PrecisionTM a 
total of 4 plans were chosen covering all 3 collimator 
types (Fixed, Iris and MLC) as well as all dose calculation 
algorithms (Raytracing (RT), finite-pencil-beam (FSPB) 
and Monte Carlo (MC)). The following operations were 
performed 3 times per plan within MultiPlanTM as well as 
within PrecisionTM and the time needed to perform these 
operations was quantified: open and save a plan, 
optimize a plan, calculate a dose distribution (RT, FSPB 
and MC) and time reduction. A speedup-factor was 
calculated giving the ratio between the time quantified 
within MultiPlanTM and the time quantified within 
PrecisionTM. 
Results  
The upgrade was scheduled for 10 days in total including 
6 days of downtime. The successful installation of the 
new hard- and software was done during the first 5 days 
followed by 2 days of quality assurance (QA) in order to 
approve the new system for clinical use. The remaining 3 
days were used for training and go-live. 5 days were 
needed in order to perform the commissioning of the MC 
algorithm for the InCiseTM MLC.  
For our institution, the 5 most important new features in 
CK-11 are the following: Possibility to perform 
deformable image registration (DIR) between CT and MR, 
improved auto-segmentation tools, MC dose calculation 
option for the InCiseTM MLC, the availability to take into 
account prior dose distributions within the planning 
process when retreating patients and the automatic 
startup-option for the Cyberknife. 
In comparison to MultiPlanTM the performance of 
PrecisionTM was increased by a speedup-factor of 3.4 (2.5 
- 4.4) to open and save a plan, 1.5 (1.1-2.2) to optimize a 
plan, 7.3 (7.2-7.4) to calculate an MC dose, 1.7 (1.6-1.8) 
to calculate a Raytracing dose, 3.3 (3.1 - 3.4) to 
calculate a FSPB dose and 5.5 (0.6-14.1) to perform a 
time reduction while dosimetric results keep the 
same.Conclusion  
The CK-11 upgrade was performed successfully and in 
time. The CK-11 version offers clinical benefits due to 
improved segmentation quality (DIR), saving time in the 
treatment planning process (auto-segmentation, 
improved TPS performance) and more accurate dose 
calculation (MC for InCiseTM MLC). 
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